Datopotamab Deruxtecan, often abbreviated as DATO, represents the notable advancement within targeted cancer treatment. This novel antibody-drug conjugate pairs a monoclonal immunoglobulin specifically directed at HER2 https://www.targetmol.com/compound/datopotamab